US 7,547,716 B2Granted

Sulfonamide derivatives

AssigneeInstitute of Medicinal Molecular Design, Inc.

InventorsSusumu Muto, Masayuki Komukai, Akiko Itai

Life of this patent

Estimating the term…

Loading patent…

Abstract

A medicament for enhancing an effect of a cancer therapy based on a mode of action of DNA injury, which comprises as an active ingredient a compound represented by the general formula (I) or a physiologically acceptable salt thereof: wherein R represents an aryl-substituted alkyl group, an heteroaryl-substituted alkyl group, a cycloalkyl-substituted alkyl group, or a cyclic hydrocarbon group wherein said cyclic hydrocarbon group may be saturated, partly saturated, or aromatic; or Z may bind to R to form a cyclic structure, Z represents a hydrogen atom or a C1 to C6 alkyl group. The medicament enhanced the effect of the cancer therapy and decreases a dose of an anticancer agent and/or radiation, and therefore, can reduce side effects resulting from the cancer therapy.

Claims9

Dependent claims

A compound represented by the general formula (II) or a salt thereof:

wherein A represents a C6 to C10 aryl group which may be substituted, or a 4 to 10-membered monocyclic or bicyclic and unsaturated, partly saturated, or completely saturated heterocyclic group which may be substituted, wherein said heterocyclic group comprises 1 to 4 hetero atoms selected from the group consisting of nitrogen atom, oxygen atom, and sulfur atom;
B represents a single bond or a methylene group which may be substituted;
and W and X independently represent a hydrogen atom or a C1 to C6 alkyl group which may be substituted, or W may combine with a substituent of A to represent a C1 to C4 alkylene group wherein said alkylene group may be substituted;
Y represents a hydrogen atom or a C1 to C6 alkyl group which may be substituted, or Y may combine with a substituent of A to represent a C1 to C4 alkylene group wherein said alkylene group may be substituted;
and n represents 1;
provided that the following compound is excluded:
5-amino-N-(phenylmethyl)-1-naphthalenesulfonamide.

4 more elements

Dependencies are inferred from the claim text.

Facts

Application: 10/478,687Filed 7 Jun 2002
Priority: JP 2001-1740668 Jun 2001
Published: US 2004/0234622 A125 Nov 2004
Granted: 16 Jun 2009
Term ends: Not estimatedThe source records don’t support an estimate.

Classification32 codes

C07D 213/42
Radicals substituted by singly-bound nitrogen atoms: having hetero atoms attached to the substituent nitrogen atom
A61K 31/18
Amides, e.g. hydroxamic acids: sulfonamides
A61K 31/341
Having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide: not condensed with another ring, e.g. ranitidine,…
A61K 31/36
Having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel: compounds containing methylenedioxyphenyl groups, e.g. sesamin